Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:16 PM
Ignite Modification Date:
2025-12-24 @ 12:16 PM
NCT ID:
NCT04991961
Eligibility Criteria:
Inclusion Criteria:
* Persistent hypertension \>150/100mmHg, including previously diagnosed grade 2 hypertension but well controlled by 1-2 drugs; newly diagnosed hypertension with 3 days blood pressure \> 150 / 100mmHg
* Resistant hypertension(combined with three antihypertensive drugs and one of them is diuretic but blood pressure is still greater than 140 / 90 mmHg ; or need to combined four anti-hypertensive drugs to control the blood pressure under 140 / 90 mmHg)
* Family history of hypertension with early onset (\< 40 years old)
* Family history of hypertension with early onset (\<40 years old) and cerebrovascular accident
* Hypertension with spontaneous or diuretic hypokalemia
* Hypertensive with adrenal incidentaloma
* Hypertensive with OSAS
* First-degree relatives of PA patients and with hypertension Stable antihypertensive medication therapy for more than 2 weeks, medication including：β-blockers, CCB, ACEi, ARB, MRA, and other diuretics.
Exclusion Criteria:
* Patients hard to change or stop the medication for accomplish the screening test or diagnosis Unwilling to participate the study and refuse to sign on informed consent Patients who was diagnosed with other secondary hypertension Suspected with PA（rein concretion beyond the limit of normal reference range after stoping or changing the medication） Severe renal insufficiency （eGFR\<30 ml/min/1.73m2）; pregnancy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
10 Years
Maximum Age:
90 Years
Study:
NCT04991961
Study Brief:
Protocol Section:
NCT04991961